vs

Side-by-side financial comparison of Crown Castle (CCI) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Crown Castle is the larger business by last-quarter revenue ($1.0B vs $622.0M, roughly 1.6× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -45.9%, a 80.4% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -4.5%).

Crown Castle Inc. is a real estate investment trust and provider of shared communications infrastructure in the United States headquartered in Houston, Texas. Operating with 100 offices worldwide, its network includes over 40,000 cell towers and approximately 85,000 route miles of fiber supporting small cells and fiber systems.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

CCI vs RPRX — Head-to-Head

Bigger by revenue
CCI
CCI
1.6× larger
CCI
$1.0B
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+9.6% gap
RPRX
4.8%
-4.8%
CCI
Higher net margin
RPRX
RPRX
80.4% more per $
RPRX
34.4%
-45.9%
CCI
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-4.5%
CCI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CCI
CCI
RPRX
RPRX
Revenue
$1.0B
$622.0M
Net Profit
$-464.0M
$214.2M
Gross Margin
Operating Margin
46.0%
62.4%
Net Margin
-45.9%
34.4%
Revenue YoY
-4.8%
4.8%
Net Profit YoY
2.9%
EPS (diluted)
$1.48
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCI
CCI
RPRX
RPRX
Q1 26
$1.0B
Q4 25
$1.1B
$622.0M
Q3 25
$1.1B
$609.3M
Q2 25
$1.1B
$578.7M
Q1 25
$1.1B
$568.2M
Q4 24
$1.1B
$593.6M
Q3 24
$1.1B
$564.7M
Q2 24
$1.1B
$537.3M
Net Profit
CCI
CCI
RPRX
RPRX
Q1 26
$-464.0M
Q4 25
$294.0M
$214.2M
Q3 25
$323.0M
$288.2M
Q2 25
$291.0M
$30.2M
Q1 25
$-464.0M
$238.3M
Q4 24
$208.2M
Q3 24
$303.0M
$544.0M
Q2 24
$251.0M
$102.0M
Gross Margin
CCI
CCI
RPRX
RPRX
Q1 26
Q4 25
97.4%
Q3 25
97.2%
Q2 25
97.5%
Q1 25
97.4%
Q4 24
97.7%
Q3 24
97.6%
Q2 24
97.7%
Operating Margin
CCI
CCI
RPRX
RPRX
Q1 26
46.0%
Q4 25
48.8%
62.4%
Q3 25
49.0%
70.1%
Q2 25
47.7%
36.3%
Q1 25
49.1%
94.0%
Q4 24
51.0%
60.9%
Q3 24
47.5%
Q2 24
44.7%
50.2%
Net Margin
CCI
CCI
RPRX
RPRX
Q1 26
-45.9%
Q4 25
27.5%
34.4%
Q3 25
30.1%
47.3%
Q2 25
27.5%
5.2%
Q1 25
-43.7%
41.9%
Q4 24
35.1%
Q3 24
27.1%
96.3%
Q2 24
22.7%
19.0%
EPS (diluted)
CCI
CCI
RPRX
RPRX
Q1 26
$1.48
Q4 25
$0.67
$0.49
Q3 25
$0.74
$0.67
Q2 25
$0.67
$0.07
Q1 25
$-1.07
$0.55
Q4 24
$0.46
Q3 24
$0.70
$1.21
Q2 24
$0.58
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCI
CCI
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$55.0M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
Total Assets
$31.4B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCI
CCI
RPRX
RPRX
Q1 26
$55.0M
Q4 25
$99.0M
$618.7M
Q3 25
$57.0M
$938.9M
Q2 25
$94.0M
$631.9M
Q1 25
$60.0M
$1.1B
Q4 24
$100.0M
$929.0M
Q3 24
$194.0M
$950.1M
Q2 24
$155.0M
$1.8B
Total Debt
CCI
CCI
RPRX
RPRX
Q1 26
Q4 25
$21.6B
$9.0B
Q3 25
$21.6B
$8.9B
Q2 25
$22.0B
$8.0B
Q1 25
$22.9B
$7.6B
Q4 24
$23.5B
$7.6B
Q3 24
$23.5B
$7.6B
Q2 24
$22.9B
$7.6B
Stockholders' Equity
CCI
CCI
RPRX
RPRX
Q1 26
Q4 25
$-1.6B
$9.7B
Q3 25
$-1.5B
$9.6B
Q2 25
$-1.4B
$9.5B
Q1 25
$-1.3B
$9.8B
Q4 24
$-133.0M
$10.3B
Q3 24
$5.3B
$10.3B
Q2 24
$5.7B
$9.8B
Total Assets
CCI
CCI
RPRX
RPRX
Q1 26
$31.4B
Q4 25
$31.5B
$19.6B
Q3 25
$31.5B
$19.3B
Q2 25
$31.6B
$18.3B
Q1 25
$31.8B
$17.6B
Q4 24
$32.7B
$18.2B
Q3 24
$38.0B
$18.0B
Q2 24
$38.2B
$17.7B
Debt / Equity
CCI
CCI
RPRX
RPRX
Q1 26
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
4.43×
0.74×
Q2 24
4.04×
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCI
CCI
RPRX
RPRX
Operating Cash FlowLast quarter
$827.1M
Free Cash FlowOCF − Capex
$-43.0M
FCF MarginFCF / Revenue
-4.3%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$4.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCI
CCI
RPRX
RPRX
Q1 26
Q4 25
$3.1B
$827.1M
Q3 25
$714.0M
$702.6M
Q2 25
$832.0M
$364.0M
Q1 25
$641.0M
$596.1M
Q4 24
$2.9B
$742.5M
Q3 24
$699.0M
$703.6M
Q2 24
$768.0M
$658.2M
Free Cash Flow
CCI
CCI
RPRX
RPRX
Q1 26
$-43.0M
Q4 25
$2.9B
Q3 25
$671.0M
Q2 25
$792.0M
Q1 25
$601.0M
Q4 24
$2.8B
Q3 24
$661.0M
Q2 24
$729.0M
FCF Margin
CCI
CCI
RPRX
RPRX
Q1 26
-4.3%
Q4 25
268.4%
Q3 25
62.6%
Q2 25
74.7%
Q1 25
56.6%
Q4 24
247.3%
Q3 24
59.0%
Q2 24
65.9%
Capex Intensity
CCI
CCI
RPRX
RPRX
Q1 26
1.0%
Q4 25
17.0%
Q3 25
4.0%
Q2 25
3.8%
Q1 25
3.8%
Q4 24
15.7%
Q3 24
3.4%
Q2 24
3.5%
Cash Conversion
CCI
CCI
RPRX
RPRX
Q1 26
Q4 25
10.40×
3.86×
Q3 25
2.21×
2.44×
Q2 25
2.86×
12.06×
Q1 25
2.50×
Q4 24
3.57×
Q3 24
2.31×
1.29×
Q2 24
3.06×
6.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCI
CCI

Site rental$961.0M95%
Services and other$49.0M5%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons